20 Phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR mutant non-small cell lung cancer (NSCLC): Analysis of adverse events (AEs)
In: Journal of Thoracic Oncology, Jg. 18 (2023-04-01), Heft 4, Number 4 Supplement 1, S. S36
Online
serialPeriodical
Zugriff:
Titel: |
20 Phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR mutant non-small cell lung cancer (NSCLC): Analysis of adverse events (AEs)
|
---|---|
Autor/in / Beteiligte Person: | Gandhi, S.J. |
Link: | |
Zeitschrift: | Journal of Thoracic Oncology, Jg. 18 (2023-04-01), Heft 4, Number 4 Supplement 1, S. S36 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1556-0864 (print) ; 1556-1380 (print) |
DOI: | 10.1016/S1556-0864(23)00256-3 |
Sonstiges: |
|